在驱动基因阳性NSCLC中针对性治疗耐药后的组织学转变:机制和治疗挑战
Xinyue Li1,2, Kaibo Ding3, Dujiang Liu1,2
1Department of Medical Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
Therapeutic advances in medical oncology
|September 4, 2025
概括
非小细胞肺癌 (NSCLC) 的药物耐药性可能导致组织学转化为更具攻击性的亚型. 本综述探讨了这些转变,它们的机制以及改善患者结果的治疗策略.
科学领域:
- 癌症学
- 分子生物学
- 癌症研究
背景情况:
- 针对性治疗改善了非小细胞肺癌 (NSCLC) 患者的治疗结果.
- 药物耐药性仍然是一个重大挑战,往往导致组织学转变.
- 转变的NSCLC亚型表现出增加的攻击性和治疗耐药性.
研究的目的:
- 系统地审查针对性治疗后NSCLC的组织变异类型.
- 解释这些变化的复杂分子机制.
- 总结目前和新兴的转化NSCLC的治疗策略.
主要方法:
- 对NSCLC组织转化研究的系统文献综述.
- 分子机制的分析,包括RB1/TP53无活化和上皮介质转换.
- 对转化后NSCLC的治疗方法的审查.
主要成果:
- 组织学转化为小细胞肺癌,大细胞神经内分泌癌,状细胞癌和肉类瘤是关键的抵抗机制.
- 分子驱动因素包括RB1/TP53无活化和上皮介质转变.
- 转变后的瘤具有有限的治疗选择和较差的预后.
结论:
- 在针对性治疗的NSCLC中,组织学转化是一个关键的挑战.
- 了解分子机制对于开发有效治疗至关重要.
- 需要个性化治疗策略来解决转化NSCLC的复杂性.
相关概念视频
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K